Syahril Abdullah

  • Research Overview

    The main focus of our research team is on the development of gene and stem cell therapy with the primary aim of developing treatment for a blood disorder. Over the past few years, we have been focusing our efforts to overcome problems such as; (1) extending the duration of therapeutic gene expression and, (2) improving the safety features of the gene delivery vectors. 

    We have found that the transgene expression in hematopoietic stem cells mediated by Lentiviral gene delivery was transient in vitro and following transplantation into mice. This was due to the epigenetic influences at the regulatory sequence and the reporter gene, together with the effects at the chromatin level.  To overcome this problem, we have tested a Lentiviral vector carrying zero-CpG reporter gene. Unfortunately, the results were modest. Further refinement on the Lentiviral construct is being done. We are also in the midst of transducing pluripotent cell lines to determine the transgene expression profiles and to study the epigenetic influences on the transgene

    Our group has recently generated induced Pluripotent Stem cell (iPS cells) line from mouse-tail fibroblast using a polycistron Lentiviral vector carrying four transcription factors. With the ability to produce such cell, we envision to combine the gene therapy approach with iPS cells for safe, effective and permanent disease correction.        

    Improvement in the duration of transgene expression and safety features have been shown with the use of CpG depleted non-viral vector in many organs. Such vector is currently used in a clinical trial for Cystic Fibrosis gene therapy in the United Kingdom. Our group is studying the CpG-depleted non-viral vector to determine its effectiveness in different models and to ascertain the mechanisms of prolonged transgene expression.      

    The ability of adult cells to trans-differentiate into a different type of cells by natural mean in culture is also intriguing. We are learning this process in hope to be able to produce and isolate our cell of interest in the near future.

    We are also interested in discovering novel gene carrier to the lung. At the moment, we are focusing our research on nanoparticles such as dextran-spermine and carbonate apatite. We hope that plasmid DNA encapsulated into a nanosized particle will enter the lung cells more efficiently compared to its larger-sized counterparts.

    Research Funding

    Project Title Funding Source
    Defining bronchoalveolar stem cells as the lung stem cells using clonogenic assay in murine lung. UPM
    Study on the persistency of transgene expression mediated by lentiviral gene delivery in pluripotent cell lines. Ministry of Science, Technology & Innovation Malaysia (MOSTI)
    Correction of β-thalassemia in mouse model by autologous transplantation of hematopoietic stem cell derived from induced pluripotent stem cells. Ministry of Education (MoE) Malaysia
    Studies on the mechanisms of transgene silencing in HSCs following lentiviral gene transfer. UPM
    Development of vector with persistent transgene expression for HSCs gene transfer. Ministry of Science, Technology & Innovation Malaysia (MOSTI)

    Selected Publications

    [publication publisher=”Syahril Abdullah”][/publication]


    Year Name of Award
    2009 Highest Impact Factor for Publication – UPM
    2009 Anugerah Penyelidik Cemerlang – UPM
    2010 Anugerah Penyelidik Harapan – Institute of Biosciences UPM
    2012 Best Poster Award – Tissue Engineering & Regenerative Medicine Society of Malaysia
    2012 Member of the Young Scientist Network/Academy of Sciences Malaysia


    Date Granted Title Owner Country Number
    2010-03-31 A Drug Delivery System in Bone Tissue Universiti Putra Malaysia & Malaysian Nuclear Agency Malaysia PCT/MY2010/000044
    2009-12-09 An Anticancer Agent Universiti Putra Malaysia Malaysia PCT/MY2009/000204
    pending Prenatal Screening of Down Syndrome Thilakavathy Karuppiah and Rozita Rosli Malaysia PI20061883 (file no.)- 25/04/06
    19 Dec. 2013. An oral DNA vaccine for cholera. Rozita Rosli, Mariana Nor Shamsudin, Syahril Abdullah Malaysia. PI2013702493.
    05 July 2012 Gold nanoparticles for use in therapeutic methods. Syahril Abdullah, Dhayanand Dorasamy, Rozita Rosli. Malaysia. PI2012003058.

    Current Lab Members

    Name Position Research Interest Year Joined
    Akram Faisal Mahmaud PhD Student
    Muhammad Omar Bin Habib RAHUMAN Student Gene Expression Profiles of CpG Motifs Depleted Plasmid DNA 2014
    Suleiman Yusuf Alhaji Postgraduate Student Persistency of Trangene Expression Mediated by Lentiviral Gene Delivery in Pluripotent cell lines 2013
    Wai Yeng (Wendy) Yeo PhD Differentiation of Muscle-Derived Stem Cells into Beta Pancreatic Lineage 2009
  • Syahril Abdullah

    [email protected]
    Gene Therapy

    +603 8947 2423